Ucommune International (NASDAQ:UK) versus OptimizeRx (NASDAQ:OPRX) Head to Head Survey

OptimizeRx (NASDAQ:OPRX) and Ucommune International (NASDAQ:UK) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares OptimizeRx and Ucommune International”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$71.52 million	1.40	-$17.57 million	($1.33)	-4.08
Ucommune International	$64.76 million	0.01	-$690,000.00	N/A	N/A

Ucommune International has lower revenue, but higher earnings than OptimizeRx.

Analyst Recommendations

This is a summary of current ratings and target prices for OptimizeRx and Ucommune International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0	3	6	0	2.67
Ucommune International	0	0	0	0	0.00

OptimizeRx presently has a consensus target price of $9.06, suggesting a potential upside of 66.90%. Given OptimizeRx’s stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than Ucommune International.

Volatility and Risk

OptimizeRx has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Ucommune International has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Profitability

This table compares OptimizeRx and Ucommune International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-27.41%	-4.92%	-3.41%
Ucommune International	N/A	N/A	N/A

Institutional and Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 36.9% of Ucommune International shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders. Comparatively, 14.2% of Ucommune International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

OptimizeRx beats Ucommune International on 7 of the 12 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About Ucommune International

Ucommune International Ltd manages and provides agile office spaces in China. It operates self-operated and asset-light models. The company also provides individual services, such as catering, fitness, healthcare, training, and entertainment; general corporate services, such as corporate secretary, human resources, legal, finance, IT support, and tax services; incubation and corporate venturing services; design and build services; advertising and branding services; and related services. It serves individuals and enterprises. The company operates under the Ucommune brand. Ucommune International Ltd was founded in 2015 and is based in Beijing, the People's Republic of China.